BMS Reports Data from the P-III (YELLOWSTONE) Study of Zeposia to Treat Moderate to Severe Active Crohn’s Disease
Shots:
- The P-III (YELLOWSTONE) trial assesses the safety & efficacy of Zeposia (0.92mg, oral) vs PBO for treating moderate to severe active Crohn’s Disease. It comprises of two 12wks. induction studies (n=~600 each), a 52wks. maintenance study (includes induction study responders) & a 264wks. extension study (includes non-responders & those who conclude maintenance study)
- The induction trial’s 1EP includes patients with a CDAI score of <150 and the maintenance trial’s co-1EPs are patients with a CDAI score of <150 & SES-CD score decrease by at least 50% from baseline
- The trial did not achieve clinical remission at wk.12 and showed Zeposia’s consistent safety profile with its previous evaluations. Full assessment is underway
Ref: BMS | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
